Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : PhaseBio Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : BioVectra will provide its integrated CDMO services for the manufacturing of the active pharmaceutical ingredient (API) of bentracimab for use in PhaseBio’s ongoing global clinical trials and for global commercial use upon regulatory approval.
Brand Name : PB2452
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 11, 2021
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : PhaseBio Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?